Intestinal nutrient sensing and blood glucose control

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 18, Issue 4, 2015, Pages 381-388

  Zietek, Tamara ^a   Daniel, Hannelore ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bariatric surgery; Diabetes; Gut hormones; Hyperglycemia; Incretins; Insulin; Receptors; Transporters

Indexed keywords

CHOLECYSTOKININ; FASIGLIFAM; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; METFORMIN; PEPTIDE YY; SHORT CHAIN FATTY ACID; SITAGLIPTIN; CARBOHYDRATE DIET; GLUCOSE BLOOD LEVEL; INCRETIN; PROTEIN INTAKE; VOLATILE FATTY ACID;

ADIPOSE TISSUE; APOPTOSIS; APPETITE; BARIATRIC SURGERY; BODY WEIGHT; CELL FUNCTION; DIETARY FIBER; ENERGY EXPENDITURE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HUMAN; INSULIN RELEASE; LIPID STORAGE; MICROFLORA; NEUROPROTECTION; NONHUMAN; NUTRIENT SENSING; OSSIFICATION; PANCREAS ISLET BETA CELL; PANCREAS SECRETION; REVIEW; STOMACH ACID SECRETION; STOMACH EMPTYING; STOMACH MOTILITY; SYSTOLIC BLOOD PRESSURE; ANIMAL; CARBOHYDRATE DIET; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; ENTEROENDOCRINE CELL; INTESTINE; INTESTINE FLORA; METABOLISM; MICROBIOLOGY; PROTEIN INTAKE; SECRETION (PROCESS);

ANIMALS; BARIATRIC SURGERY; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIETARY CARBOHYDRATES; DIETARY FIBER; DIETARY PROTEINS; DISEASE MODELS, ANIMAL; ENTEROENDOCRINE CELLS; FATTY ACIDS, VOLATILE; GASTROINTESTINAL MICROBIOME; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INTESTINES;

EID: 84942781740     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000187     Document Type: Review

References (58)

1. Alberti KG, Zimmet PZ. Diabetes: A look to the future. Lancet Diabetes Endocrinol 2014; 2: 1-2.
2. Drucker DJ. Deciphering metabolic messages from the gut drives therapeutic innovation: The 2014 banting lecture. Diabetes 2015; 64: 317-326.
3. Breen DM, Rasmussen BA, Cote CD, et al. Nutrient-sensing mechanisms in the gut as therapeutic targets for diabetes. Diabetes 2013; 62: 3005-3013.
4. Ezcurra M, Reimann F, Gribble FM, Emery E. Molecular mechanisms of incretin hormone secretion. Curr Opin Pharmacol 2013; 13: 922-927.
5. Habib AM, Richards P, Cairns LS, et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 2012; 153: 3054-3065.
6. Egerod KL, Engelstoft MS, Grunddal KV, et al. A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology 2012; 153: 5782-5795.
7. Sykaras AG, Demenis C, Cheng L, et al. Duodenal CCK cells from male mice express multiple hormones including ghrelin. Endocrinology 2014; 155: 3339-3351.
8. Reimann F, Tolhurst G, Gribble FM. G-protein-coupled receptors in intestinal chemosensation. Cell Metab 2012; 15: 421-431.
9. Bala V, Rajagopal S, Kumar DP, et al. Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-epsilon pathway and modulated by endogenous H2S. Front Physiol 2014; 5: 420.
10. Parker HE, Wallis K, le Roux CW, et al. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol 2012; 165: 414-423.
11. Parker HE, Adriaenssens A, Rogers G, et al. Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia 2012; 55: 2445-2455.
12. Gorboulev V, Schurmann A, Vallon V, et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 2012; 61: 187-196.
13. Roder PV, Geillinger KE, Zietek TS, et al. The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PloS one 2014; 9: E89977.
14. Kuhre RE, Frost CR, Svendsen B, Holst JJ. Molecular mechanisms of glucose- Stimulated GLP-1 secretion from perfused rat small intestine. Diabetes 2015; 64: 370-382.
15. Mace OJ, Schindler M, Patel S. The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CasR in rat small intestine. J Physiol 2012; 590 (Pt 12): 2917-2936.
16. Tarussio D, Metref S, Seyer P, et al. Nervous glucose sensing regulates postnatal beta cell proliferation and glucose homeostasis. J Clin Invest 2014; 124: 413-424.
17. Delaere F, Duchampt A, Mounien L, et al. The role of sodium-coupled glucose co-transporter 3 in the satiety effect of portal glucose sensing. Mol Metab 2012; 2: 47-53.
18. Hoefle AS, Bangert AM, Stamfort A, et al. Metabolic responses of healthy or prediabetic adults to bovine whey protein and sodium caseinate do not differ. J Nutr 2015; 145: 467-475.
19. Diakogiannaki E, Pais R, Tolhurst G, et al. Oligopeptides stimulate glucagonlike peptide-1 secretion in mice through proton-coupled uptake and the calcium-sensing receptor. Diabetologia 2013; 56: 2688-2696.
20. Iwasaki K, Harada N, Sasaki K, et al. Free fatty acid receptor GPR120 is highly expressed in enteroendocrine K-cells of the upper small intestine and has a critical role in GIP secretion after fat ingestion. Endocrinology 2014; 156: 837-846.
21. Itoh K, Moriguchi R, Yamada Y, et al. High saturated fatty acid intake induces insulin secretion by elevating gastric inhibitory polypeptide levels in healthy individuals. Nutr Res 2014; 34: 653-660.
22. Nohr MK, Pedersen MH, Gille A, et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology 2013; 154: 3552-3564.
23. Sommer CA, Mostoslavsky G. RNA-Seq analysis of enteroendocrine cells reveals a role for FABP5 in the control of GIP secretion. Mol Endocrinol 2014; 28: 1855-1865.
24. Shibue K, Yamane S, Harada N, et al. Fatty acid binding protein 5 (FABP5) regulates diet-induced obesity (DIO) via GIP secretion from enteroendocrine K-cells in response to fat ingestion. Am J Physiol Endocrinol Metab 2015; 308: 583-591.
25. Hauge M, Vestmar MA, Husted AS, et al. GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. Mol Metab 2015; 4: 3-14.
26. Urban C, Hamacher A, Partke HJ, et al. In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469. Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 1021-1030.
27. Takano R, Yoshida M, Inoue M, et al. Discovery of DS-1558: A potent and orally bioavailable GPR40 agonist. ACS Med Chem Lett 2015; 6: 266-270.
28. Oh da Y, Walenta E, Akiyama TE, et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nature Med 2014; 20: 942-947.
29. Ito R, Tsujihata Y, Matsuda-Nagasumi K, et al. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and beta-cell dysfunction in Zucker diabetic fatty rats. British J Pharmacol 2013; 170: 568-580.
30. Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: First clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14: 271-278.
31. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012; 379: 1403-1411.
32. Wang Y, Liu JJ, Dransfield PJ, et al. Discovery and optimization of potent GPR40 full agonists containing tricyclic spirocycles. ACS Med Chem Lett 2013; 4: 551-555.
33. Watterson KR, Hudson BD, Ulven T, Milligan G. Treatment of type 2 diabetes by free fatty acid receptor agonists. Front Endocrinol 2014; 5: 137.
34. Luo J, Swaminath G, Brown SP, et al. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PloS One 2012; 7: E46300.
35. Lin DC, Guo Q, Luo J, et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol 2012; 82: 843-859.
36. Tanaka H, Yoshida S, Minoura H, et al. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion. Life Sci 2014; 94: 115-121.
37. Kaji I, Karaki S, Tanaka R, Kuwahara A. Density distribution of free fatty acid receptor 2 (FFA2)-expressing and GLP-1-producing enteroendocrine L cells in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide, Journal of molecular histology. J Mol Histol 2011; 42: 27-38.
38. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012; 61: 364-371.
39. Hudson BD, Due-Hansen ME, Christiansen E, et al. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem 2013; 288: 17296-17312.
40. Everard A, Lazarevic V, Derrien M, et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011; 60: 2775-2786.
41. Neyrinck AM, Possemiers S, Verstraete W, et al. Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice. J Nutr Biochem 2012; 23: 51-59.
42. De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014; 156: 84-96.
43. Meyer-Gerspach AC, Wolnerhanssen B, Beglinger C. Gut sweet taste receptors and their role in metabolism. Front Horm Res 2014; 42: 123-133.
44. Young RL, Chia B, Isaacs NJ, et al. Disordered control of intestinal sweet taste receptor expression and glucose absorption in type 2 diabetes. Diabetes 2013; 62: 3532-3541.
45. Laffitte A, Neiers F, Briand L. Functional roles of the sweet taste receptor in oral and extraoral tissues. Curr Opin Clin Nutr Metab Care 2014; 17: 379-385.
46. Shirazi-Beechey SP, Daly K, Al-Rammahi M, et al. Role of nutrient-sensing taste 1 receptor (T1R) family members in gastrointestinal chemosensing. Br J Nutr 2014; 111 (Suppl 1): S8-S15.
47. Geraedts MC, Takahashi T, Vigues S, et al. Transformation of postingestive glucose responses after deletion of sweet taste receptor subunits or gastric bypass surgery. Am J Physiol Endocrinol Metab 2012; 303: E464-E474.
48. Wu T, Zhao BR, Bound MJ, et al. Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans. Am J Clin Nutr 2012; 95: 78-83.
49. Ford HE, Peters V, Martin NM, et al. Effects of oral ingestion of sucralose on gut hormone response and appetite in healthy normal-weight subjects. Eur J Clin Nutr 2011; 65: 508-513.
50. Steinert RE, Frey F, Topfer A, et al. Effects of carbohydrate sugars and artificial sweeteners on appetite and the secretion of gastrointestinal satiety peptides. Br J Nutr 2011; 105: 1320-1328.
51. Brown RJ, Rother KI. Nonnutritive sweeteners and their role in the gastrointestinal tract. J Clin Endocrinol Metab 2012; 97: 2597-2605.
52. Bhutta HY, Deelman TE, le Roux CW, et al. Intestinal sweet-sensing pathways and metabolic changes after Roux-en-Y gastric bypass surgery. Am J Physiol Gastroint Liver Physiol 2014; 307: G588-G593.
53. Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 2012; 35: 1420-1428.
54. Ogawa N, Ito M, Yamaguchi H, et al. Intestinal fatty acid infusion modulates food preference as well as calorie intake via the vagal nerve and midbrainhypothalamic neural pathways in rats. Metabolism 2012; 61: 1312-1320.
55. Dailey MJ, Tamashiro KL, Terrillion CE, Moran TH. Nutrient specific feeding and endocrine effects of jejunal infusions. Obesity 2010; 18: 904-910.
56. Breen DM, Rasmussen BA, Kokorovic A, et al. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med 2012; 18: 950-955.
57. Rasmussen BA, Breen DM, Luo P, et al. Duodenal activation of cAMPdependent protein kinase induces vagal afferent firing and lowers glucose production in rats. Gastroenterology 2012; 142: 834-843; e3.
58. Blanco J, Jimenez A, Casamitjana R, et al. Relevance of beta-cell function for improved glycemic control after gastric bypass surgery. Surg Obes Relat dis 2014; 10: 9-13; quiz 189-90.